Well C1 Nerves, organs and chronic pain
Stem Cell Therapy for Systemic and Organ-Related Conditions: What Is Currently Being Explored
Contents: 6 sections
Outside of transplants for blood cancers and other blood disorders, and one donor cell product for a complication of those transplants in children, no stem cell treatment is FDA-approved for neurological, autoimmune, organ or metabolic disease. For conditions like multiple sclerosis, lupus, Parkinson’s disease or heart failure, stem cells are still experimental. The legitimate route is a properly overseen clinical trial: one with named investigators, an ethics committee, a research consent form and a registration you can look up yourself.
What is actually approved?
| Condition | Status as of September 25, 2026 | Source |
|---|---|---|
| Blood cancers and some other blood and immune disorders | Blood-forming stem cell transplants from bone marrow or cord blood are established treatment; nine cord blood products are FDA-licensed for these transplants | Mayo Clinic; FDA approved products list (updated September 17, 2026) |
| Steroid-refractory acute graft-versus-host disease in children (a complication of transplant) | RYONCIL, donor mesenchymal stromal cells, approved December 2024 | FDA |
| Neurological, autoimmune, organ and metabolic diseases, including MS, lupus, rheumatoid arthritis, Crohn's disease, ALS, Parkinson's, stroke, neuropathy, liver, kidney, heart and lung disease, and diabetes | No stem cell product approved. Investigational only | FDA approved products list (above) |
Sources for the table: Mayo Clinic; FDA approved products list; FDA.
The FDA list also includes LANTIDRA, a donor pancreatic islet cell product. Islet cells are not stem cells, and that approval does not cover any stem cell infusion.
What has the research found so far?
Some results are encouraging, but encouraging is not the same as proven. One 2025 review pooled 42 randomized trials with 2,183 participants across eight rheumatic and autoimmune conditions. It reported improvement in lupus and inflammatory bowel disease, and said that in multiple sclerosis and systemic sclerosis the cells “may not improve the symptoms” (Stem Cell Research & Therapy, 2025). None of those findings has led to an FDA approval for those diseases.
The lupus and bowel disease results are the most promising signals in that review, and they are why research continues. What would move them toward approval is larger trials that confirm the benefit in the outcomes patients care about, followed by regulatory review. The next example shows why that confirmation step matters.
Alofisel, a donor fat-derived cell product injected into Crohn’s disease fistulas near the anus, was approved in the European Union (never by the FDA). A larger trial of 568 patients then found that about 49% of treated patients met the trial’s main goal against 46% on placebo, a difference that was not statistically significant, and the product was withdrawn from the EU market in December 2024 (European Medicines Agency).
When you read a study a clinic cites, check three things:
- What was measured. A change in a lab test or scan is not the same as less pain, better walking or fewer relapses. Ask whether the trial measured the outcome you care about.
- Whether there was a control group. Improvement after treatment, or a high survival rate, means little without a comparison group that did not get the cells.
- Which product was tested. A trial result applies to the product the trial used. If the clinic’s product is different, for example a same-day or donor product instead of cells grown in a laboratory for the trial, the result does not describe what you would get.
Finding and recognizing a real clinical trial
Search ClinicalTrials.gov for your condition together with “stem cell” or “mesenchymal”, and ask the specialist who treats you, such as your neurologist or rheumatologist, about trials they know. Then check what you find:
| Good sign | Warning sign |
|---|---|
| Has an NCT number you can look up, and a research team at a hospital or university | "It's a study," with no number, or a number for a different product |
| Usually does not charge for the experimental treatment. The International Society for Stem Cell Research says "it is not customary to pay to be in a clinical trial" (ISSCR) | A fee of thousands of dollars to "participate" |
| A research consent form that describes the study | A treatment consent form with no study described |
| Encourages you to keep seeing your own specialist | Tells you to stop or change your existing treatment |
Sources for the table: <a href="https://static1.squarespace.com/static/611faaa8fee682525ee16489/t/65f09b1918aebc21ebd37efe/1710267161381/ISSCRPatientHandbookv12Feb2024Redesign_v4b.pdf”>ISSCR.
A trial listing is not an approval, and a registration shows only that a study exists, not that it is well designed or that the product works. The FDA says a ClinicalTrials.gov listing or a clinic’s registration with the agency “does not mean the product is legally marketed” (FDA). What a research consent form should contain, and how it differs from a treatment consent form, is covered on our page about reading a consent form before you sign.
What should make you walk away from a clinic?
The ISSCR lists warning signs that include heavy reliance on patient testimonials, one cell type marketed for many unrelated diseases, claims that a treatment carries no risk, and claims that regulatory approval is not needed (ISSCR, above). In practice, that sounds like this:
| What you hear | What it means |
|---|---|
| "This can cure" or "reverse" MS, Parkinson's, ALS or dementia | No stem cell treatment has been shown to do this; the FDA has approved none for these diseases |
| "We treat autoimmune, neurological and heart conditions" | One product sold for many unrelated diseases, an ISSCR warning sign |
| "Your neurologist doesn't know about this" | A claim designed to separate you from the doctor who knows your case |
| "Patients tell us they feel better" | Testimonials are not evidence; without a comparison group, improvement can come from placebo or from the natural ups and downs of a disease |
| "It's safe because the cells are natural" or "there are no side effects" | A claim of no risk, an ISSCR warning sign |
| "We're registered with the FDA" | Registration is not approval (FDA, above) |
The same warning signs apply to joint and spine clinics; the full list is on the page about signs of an unproven stem cell clinic.
What are the risks?
Infusions into a vein, the spinal fluid or an organ carry their own risks. The FDA reports “blindness, tumor formation, infections, and more” after unapproved regenerative products (FDA). In May 2026 it repeated its warning about unapproved cell and tissue products, citing reports that include deaths (FDA warning).
Another risk is what you give up. Do not stop or change treatment for multiple sclerosis, rheumatoid arthritis, lupus, Crohn’s disease, cancer or diabetes to fit an experimental procedure without the specialist who prescribes it. A clinic that asks you to time or pause those medicines around its procedure is asking you to accept a risk that the evidence for its product does not yet justify.
Should you consider it for these conditions?
For these conditions, the evidence supports trying a stem cell treatment only inside a properly overseen clinical trial, alongside the care you already have. A clinic that charges for an experimental infusion, promises improvement or asks you to change proven treatment is offering something different from a trial, whatever it calls it. How the FDA rules work for all stem cell products is explained on our page about what stem cell therapy is and what is approved, and a checklist for any regenerative clinic covers the desk checks worth doing before any visit.
This page is general information, not medical advice.